Package Leaflet User Testing: Proving Patients Can Find and Understand What Matters

Every package leaflet submitted in the EU must reflect the results of consultation with target patient groups. For many marketing authorisation applicants, that consultation means a readability user test, and a poorly planned one can delay a procedure at precisely the wrong moment.

The legal requirement

Directive 2001/83/EC, as amended by Directive 2004/27/EC, requires the package leaflet to reflect the results of consultations with target patient groups, so that it is legible, clear and easy to use. The Commission’s guideline on the readability of the label and package leaflet (revision 1, January 2009) sets out how this is expected to work in practice. Outer packaging must also carry the product name in braille under Article 56a of the Directive, which is a separate but related labelling obligation.

What a user test measures

A user test does not rewrite the leaflet. It shows whether ordinary readers can find key information and then understand it well enough to act correctly. The widely applied benchmark is that at least 90% of participants find the information and, of those, at least 90% understand it. Participants may be patients, carers or parents, and recruitment should reflect age, gender and treatment experience. Testing is generally run in rounds, with the leaflet revised between rounds, and can be carried out in any language provided the report is available in that language.

Choosing the right type of test

  • Full user test: the whole leaflet, including layout, is tested with participants.
  • Bridging: a leaflet is compared with one already tested. This only works where text and layout are genuinely identical to the reference product, and several chained bridges become hard to defend.
  • Focus test: only part of the leaflet is tested, for example after a safety-related change to a specific section.

In some cases a new test is simpler than constructing a bridging argument. The decision should be made early, before the dossier timeline is fixed.

Common planning mistakes

  • Starting the test after the text is frozen, leaving no room for revisions between rounds.
  • Testing a draft that differs from the QRD template or the final labelling.
  • Selecting key safety messages that do not reflect the product’s actual risk profile.
  • Assuming a test performed in one language or market automatically covers another.
  • Overlooking braille and mock-up checks until the final artwork stage.

How PQRA helps

PQRA supports marketing authorisation applicants and holders with labelling strategy, QRD-aligned leaflet drafting, selection of the appropriate user-test approach (full, bridging or focus), coordination with specialist testing providers, and integration of results into the Module 1 dossier for EOF and EMA submissions. We help you plan the work early, so the leaflet is a strength of your application rather than a late-stage risk.

Contact PQRA to discuss your labelling and package leaflet plans.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *